Clinical trial
Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Locally Advanced Mid-to-low Rectal Cancer: An Open-label, Multi-center, Randomized Controlled Trial
NCT07900061 is registered in ClinicalTrials.gov with Sir Run Run Shaw Hospital as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started October 2026. Interventional study, Phase 3, 210 participants (estimated). Lead sponsor Sir Run Run Shaw Hospital. Primary measure: Disease Free Survival (DFS).
How it compares
213 similar trials: same condition (Rectal Neoplasms) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Locally Advanced Mid-to-low Rectal Cancer: An Open-label, Multi-center, Randomized Controlled Trial
- Lead sponsor
- Sir Run Run Shaw Hospital
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- October 25, 2026
- Completion date
- December 31, 2034
- Enrollment
- 210 (estimated)
- Sites
- Not reported
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: rectal cancer
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Lead sponsor
- Sir Run Run Shaw Hospital
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| node-sparing modified short course radiotherapy combined with tislelizumab and CAPOX | Experimental | node-sparing modified short-course radiotherapy |
Show registry wordingRadiotherapy: modified short-course radiotherapy for 5 days. CAPOX: Oxaliplatin 130 mg/m², once ivgtt on Day 1; Capecitabine 1000 mg/m², bid po from Day 1 to Day 14; q3w. Tislelizumab: 200 mg, ivgtt on Day 1; q3w. Treatment cycles are repeated every 3 weeks for a total of 4 cycles. | ||
| standard short course radiotherapy combined with CAPOX | Active comparator | standard short-course radiotherapy |
Show registry wordingstandard short-course radiotherapy for 5 days. CAPOX: Oxaliplatin 130 mg/m², once ivgtt on Day 1; Capecitabine 1000 mg/m², bid po from Day 1 to Day 14; q3w. Treatment cycles are repeated every 3 weeks for a total of 4 cycles. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Disease Free Survival (DFS) | up to 5 years |
Show registry wordingTime from randomization to the first occurrence of locoregional recurrence, distant metastasis, new invasive primary colorectal carcinoma or death from any cause, whichever occurs first. | |
Lead sponsor's other trials
Sir Run Run Shaw Hospital, most recent start first.
+129 more trials See the organization page
Similar trials
Same condition (Rectal Neoplasms) and phase, most recent start first.
+208 more trials See the condition page